Jardiance and Ofev propel Boehringer’s human pharma sales
Boehringer Ingelheim reported robust sales in 2023, with a 10.3% increase in human pharma sales that was strongly driven by…
All articles by Akosua Mireku
Akosua Mireku
@AkosuaMireku1
Akosua Mireku is a healthcare reporter for Pharmaceutical Technology. Akosua has a Bsc in medical physiology from the University of Manchester. She is particularly interested in topics in neuroscience, rare diseases, and global health equality
-
-
UK charities condemn continued drug shortages
A handful of UK charities and community pharmacists urged the UK government to find a fix for the ongoing drug…
-
Novartis plans to axe 680 employees
Novartis declared plans to lay off approximately 680 staff members in its development organisation on 9 April. The workforce reductions…
-
Pluri launches manufacturing division as cell therapy pipeline progresses
Israeli cell technology company Pluri has expanded its cell-based product operations in a bid to support other companies with their…
-
Incannex prepares IND submission for psychotherapy asset
Incannex Healthcare is gearing up for an investigational new drug (IND) submission for a Phase IIb generalised anxiety disorder study…
-
Ipsen joins the ADC club with deal worth up to $900m
Ipsen has joined the slew of companies developing antibody-drug conjugates (ADC) with the announcement of a new global licensing agreement…
-
Xilio and Gilead partner up for IL-12 therapeutic development
Gilead Sciences and Xilio Therapeutics declared an exclusive license agreement for the development of a tumour-activated IL-12 program. Under the…
-
Esperion snags US label expansion for cardiovascular disease drugs
Esperion Therapeutics declared that the US Food and Drug Administration (FDA) has approved a label expansion for two of its…
-
Lisata clinches rare disease status for osteosarcoma drug
The US Food and Drug Administration (FDA) has granted Lisata Therapeutics a rare pediatric disease designation (RPDD) for its osteosarcoma…
-
Investors grapple with more choices in big year for pharma fundraising
Investment rounds and fundraising will likely take longer given the crowded landscape of companies wanting to raise funds, say investors.…